Novel radioligand therapy (177Lu-PSMA-617) found to be effective in phase III prostate cancer trial

In Phase III VISION trial this investigational PSMA-targeted radioligand therapy significantly improved overall & progression free survival in patients with PSMA-positive metastatic castration-resistant prostate cancer. Data to be submitted to regulatory authorities in US and EU.

Source:

Biospace Inc.